Moderna (MRNA) closed the latest trading day at $55.22, indicating a +0.77% change from the previous session's end. This change outpaced the S&P 500's 0.16% gain on the day. Meanwhile, the Dow experienced a drop of 0.37%, and the technology-dominated Nasdaq saw an increase of 0.78%. Prior to today's trading, shares of the biotechnology company had lost 18% over the past month. This has lagged the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67% in that time. Investors will be eagerly watching ...

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have lost significantly in the past couple of years due to declining sales amid low demand for the vaccine. In the past month, MRNA stock fell more than 20% after management provided an update on its business outlook for the next four years. It also announced plans to slash its research and development (R&D) budget during this period. In the past month, the stock has underperformed the industry's 2.3% ...

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA therapeutics market size has grown steadily in recent years. It will grow from $33.5 billion in 2023 to $34.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The mRNA therapeutics market size is expected to see steady growth in the next few years. It will grow to $40.69 billion in 2028 at a compound annual growth rate (CAGR) of 4%. During ...

Core Insights - The mRNA cancer vaccines and therapeutics market is projected to grow from $52.85 billion in 2023 to $61.52 billion in 2024, with a compound annual growth rate (CAGR) of 16.4% [2][11] - By 2028, the market size is expected to reach $113.41 billion, reflecting a CAGR of 16.5% [2][11] Market Growth Drivers - Growth in the mRNA cancer vaccines and therapeutics market is driven by factors such as changing lifestyles, increased funding in medical research, favorable regulatory environments, established healthcare infrastructures, and ongoing development of new therapeutic pipelines [3] - Promising clinical trial results, rising awareness of mRNA technology, significant unmet medical needs, and the potential for improved patient outcomes are expected to further fuel market growth [4][5] Market Trends - Anticipated trends include expansion into new therapeutic areas, personalized medicine approaches, advancements in mRNA delivery systems, development of multivalent mRNA vaccines, and integration of artificial intelligence in mRNA design [4] - The increasing prevalence of cancer, influenced by sedentary lifestyles and environmental factors, is expected to drive demand for mRNA cancer vaccines and therapeutics [5] Competitive Landscape - Leading companies in the mRNA cancer vaccines and therapeutics market include Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis SA, and Moderna Therapeutics Inc., among others [6][8] - Companies are focusing on innovative treatments, particularly mRNA cancer vaccines, to meet the rising demand for effective cancer therapies [6] Regional Insights - North America was the largest market for mRNA cancer vaccines and therapeutics in 2023, while Asia Pacific is anticipated to be the fastest-growing region in the forecast period [9]

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. So what: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: ...

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- __________________ WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Group 1: Moderna's Norovirus Vaccine Study - Moderna has initiated the phase III Nova 301 study for its mRNA norovirus vaccine candidate, mRNA-1403, with the first participant dosed in the United States [1] - The study aims to enroll approximately 25,000 participants globally, focusing on older adults at higher risk of norovirus infection [2][3] - Norovirus is highly contagious and a leading cause of diarrheal disease, resulting in around 200,000 deaths annually [3] Group 2: Partnership in Taiwan - Moderna has entered a joint agreement with Cenra Healthcare to promote its mRNA respiratory vaccine portfolio in Taiwan, including the COVID-19 vaccine, Spikevax [4] - Moderna will handle the manufacturing and distribution of the vaccines, while Cenra Healthcare will manage promotion and education activities [5] Group 3: Stock Performance and Rankings - Moderna's shares have decreased by 32.8% this year, contrasting with a 1.8% decline in the industry [2] - Currently, Moderna holds a Zacks Rank of 3 (Hold), while other biotech stocks like ANI Pharmaceuticals, Krystal Biotech, and Fulcrum Therapeutics have higher rankings [6]

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific expertise to guide the company's strategic direction, this also signals Dr. Langer's strong belief in the company's miss ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced they have entered into a collaboration and nonexclusive license agreement to combine Repai ...